The following is a list of the top 100 prescribed medicines by U.S. National Sales in Q1 2012. Figures include sales through both retail and hospital channels, listed by drug name and sales value in U.S. dollars.
| Rank |
Drug |
Sales ($000) |
|
|
1 ( 1) |
Plavix
Bristol-Myers Squibb Company |
1,620,790 |
2.85% |
Stats |
| 2 (1) |
Nexium
AstraZeneca Pharmaceuticals |
1,395,981 |
-3.08% |
Stats |
| 3 (1) |
Abilify
Otsuka Pharmaceutical Co. |
1,340,200 |
4.46% |
Stats |
| 4 (1) |
Singulair
Merck & Co., Inc. |
1,238,134 |
8.67% |
Stats |
| 5 (1) |
Seroquel
AstraZeneca Pharmaceuticals |
1,161,141 |
3.29% |
Stats |
| 6 (1) |
Advair Diskus
GlaxoSmithKline |
1,139,182 |
1.61% |
Stats |
| 7 (1) |
Crestor
AstraZeneca Pharmaceuticals |
1,117,904 |
2.35% |
Stats |
| 8 (1) |
Cymbalta
Eli Lilly and Company |
1,029,262 |
7.58% |
Stats |
| 9 (15) |
atorvastatin
Generic |
952,407 |
88.56% |
Stats |
| 10 |
Humira
Abbott Laboratories |
928,124 |
2.50% |
Stats |
| 11 (2) |
Remicade
Centocor Ortho Biotech, Inc |
899,453 |
10.04% |
Stats |
12 ( 1) |
Enbrel
Amgen Inc. |
890,135 |
1.92% |
Stats |
| 13 (1) |
Neulasta
Amgen Inc. |
849,971 |
3.33% |
Stats |
| 14 (13) |
Lipitor
Pfizer Inc |
840,715 |
-47.51% |
Stats |
| 15 (1) |
Rituxan
Genentech, Inc |
756,875 |
-1.91% |
Stats |
| 16 |
Copaxone
Teva Pharmaceuticals |
748,585 |
4.59% |
Stats |
| 17 (2) |
Atripla
Gilead Sciences, Inc. |
694,901 |
5.61% |
Stats |
| 18 (1) |
OxyContin
|
662,876 |
-1.05% |
Stats |
| 19 (3) |
Spiriva
Boehringer Ingelheim Pharmaceuticals, Inc |
659,818 |
8.12% |
Stats |
| 20 (1) |
Avastin
Genentech, Inc |
632,183 |
-1.92% |
Stats |
| 21 (3) |
Actos
Takeda Pharmaceuticals North America, Inc |
630,970 |
-4.52% |
Stats |
| 22 (1) |
Januvia
Merck & Co., Inc. |
583,603 |
7.89% |
Stats |
| 23 (2) |
Truvada
Gilead Sciences, Inc. |
546,098 |
8.31% |
Stats |
| 24 (3) |
Lantus
Sanofi-Aventis |
520,584 |
9.78% |
Stats |
| 25 (3) |
Diovan
Novartis Corporation |
509,615 |
12.44% |
Stats |
| 26 (11) |
Lexapro
Forest Pharmaceuticals, Inc |
491,053 |
-31.67% |
Stats |
| 27 (7) |
Epogen
Amgen Inc. |
489,570 |
-24.54% |
Stats |
| 28 (3) |
Lyrica
Pfizer Inc |
458,171 |
6.04% |
Stats |
| 29 (5) |
Lantus Solostar
Sanofi-Aventis |
448,388 |
9.81% |
Stats |
| 30 (4) |
enoxaparin
Generic |
442,263 |
-8.30% |
Stats |
| 31 (4) |
Eloxatin
Sanofi-Aventis |
431,928 |
8.38% |
Stats |
| 32 |
Celebrex
Pfizer Inc |
430,993 |
1.08% |
Stats |
| 33 |
Herceptin
Genentech, Inc |
425,687 |
-0.06% |
Stats |
| 34 (6) |
Diovan HCT
Novartis Corporation |
415,475 |
9.52% |
Stats |
| 35 (5) |
Lucentis
Genentech, Inc |
409,547 |
-6.89% |
Stats |
| 36 (15) |
Synagis
MedImmune, Inc |
396,556 |
38.30% |
Stats |
| 37 |
Namenda
Forest Pharmaceuticals, Inc |
391,638 |
2.71% |
Stats |
| 38 (2) |
Gleevec
Novartis Corporation |
391,072 |
0.13% |
Stats |
| 39 (1) |
Avonex
Biogen Idec |
388,623 |
2.22% |
Stats |
| 40 (3) |
Vyvanse
Shire US Inc |
387,167 |
11.05% |
Stats |
| 41 (2) |
olanzapine
Generic |
385,867 |
1.70% |
Stats |
| 42 (13) |
Incivek
Vertex Pharmaceuticals |
371,349 |
-16.88% |
Stats |
| 43 (1) |
One Touch Ultra
|
366,294 |
1.32% |
Stats |
| 44 |
Suboxone
Reckitt Benckiser Pharmaceuticals Inc. |
338,840 |
2.14% |
Stats |
| 45 (5) |
methylphenidate
Generic |
337,211 |
11.27% |
Stats |
| 46 |
Zetia
Merck & Co., Inc. |
328,653 |
2.67% |
Stats |
| 47 (6) |
AndroGel
Abbott Laboratories |
311,850 |
11.20% |
Stats |
| 48 (1) |
Provigil
Cephalon, Inc. |
303,029 |
-3.18% |
Stats |
| 49 |
Lidoderm
Endo Pharmaceuticals |
301,354 |
-2.46% |
Stats |
| 50 (2) |
TriCor
Abbott Laboratories |
298,834 |
-4.37% |
Stats |
| 51 (5) |
Symbicort
AstraZeneca Pharmaceuticals |
290,669 |
8.71% |
Stats |
| 52 |
Combivent
Boehringer Ingelheim Pharmaceuticals, Inc |
285,487 |
1.08% |
Stats |
| 53 (16) |
ProAir HFA
Teva Pharmaceuticals |
284,647 |
18.08% |
Stats |
| 54 (5) |
Seroquel XR
AstraZeneca Pharmaceuticals |
282,416 |
7.81% |
Stats |
| 55 (1) |
amphetamine/dextroamphetamine
Generic |
275,447 |
-1.02% |
Stats |
| 56 (8) |
Nasonex
Merck & Co., Inc. |
274,748 |
9.21% |
Stats |
| 57 (6) |
Novolog
Novo Nordisk Inc. |
266,305 |
5.67% |
Stats |
| 58 (3) |
Procrit
Janssen Pharmaceuticals, Inc |
264,190 |
-2.13% |
Stats |
| 59 (1) |
Alimta
Eli Lilly and Company |
263,024 |
1.24% |
Stats |
| 60 (2) |
Viagra
Pfizer Inc |
260,678 |
1.22% |
Stats |
| 61 (16) |
Geodon
Pfizer Inc |
260,514 |
-21.06% |
Stats |
| 62 (1) |
Rebif
|
258,088 |
-0.21% |
Stats |
| 63 (6) |
budesonide
Generic |
257,243 |
-3.57% |
Stats |
| 64 (6) |
Niaspan
Abbott Laboratories |
255,383 |
-3.28% |
Stats |
| 65 |
Humalog
Eli Lilly and Company |
244,587 |
-2.70% |
Stats |
| 66 (1) |
Flovent HFA
GlaxoSmithKline |
241,552 |
-1.45% |
Stats |
| 67 (1) |
Lovaza
GlaxoSmithKline |
239,845 |
-1.81% |
Stats |
| 68 (7) |
Levemir
Novo Nordisk Inc. |
239,576 |
9.25% |
Stats |
| 69 (5) |
Adderall XR
Shire US Inc |
239,097 |
5.88% |
Stats |
| 70 |
Neupogen
Amgen Inc. |
238,427 |
0.06% |
Stats |
| 71 (1) |
Reyataz
Bristol-Myers Squibb Company |
238,151 |
1.45% |
Stats |
| 72 (6) |
Aranesp
Amgen Inc. |
231,643 |
-5.86% |
Stats |
| 73 |
metoprolol
Generic |
231,395 |
-0.53% |
Stats |
| 74 (2) |
NovoLog FlexPen
Novo Nordisk Inc. |
227,228 |
8.96% |
Stats |
| 75 (4) |
Vytorin
Merck & Co., Inc. |
218,215 |
-7.25% |
Stats |
| 76 (7) |
Janumet
Merck & Co., Inc. |
212,596 |
8.76% |
Stats |
| 77 (1) |
Isentress
Merck & Co., Inc. |
211,526 |
2.46% |
Stats |
78 ( ) |
escitalopram
Generic |
210,171 |
 |
Stats |
| 79 (1) |
Cialis
Eli Lilly and Company |
206,996 |
3.24% |
Stats |
| 80 (3) |
Aciphex
Eisai Corporation |
203,097 |
-1.77% |
Stats |
| 81 (4) |
Pradaxa
Boehringer Ingelheim Pharmaceuticals, Inc |
201,065 |
5.13% |
Stats |
| 82 (2) |
Solodyn
Medicis Pharmaceutical Corporation |
198,909 |
2.06% |
Stats |
| 83 (4) |
fentanyl
Generic |
197,350 |
-3.34% |
Stats |
| 84 (43) |
Zyprexa
Eli Lilly and Company |
194,460 |
-48.69% |
Stats |
| 85 (4) |
Velcade
Takeda Pharmaceuticals North America, Inc |
188,583 |
4.42% |
Stats |
| 86 |
Restasis
Allergan, Inc |
188,501 |
-1.18% |
Stats |
| 87 (5) |
Lunesta
Sunovion Pharmaceuticals Inc. |
187,941 |
-4.30% |
Stats |
| 88 (1) |
acetaminophen/hydrocodone
Generic |
185,374 |
0.09% |
Stats |
| 89 (9) |
Prezista
Janssen Pharmaceuticals, Inc |
182,859 |
9.20% |
Stats |
| 90 (1) |
Pegasys
Genentech, Inc |
181,693 |
3.92% |
Stats |
| 91 (2) |
Zyvox
Pfizer Inc |
179,523 |
3.85% |
Stats |
| 92 (4) |
Prevnar 13
Wyeth |
179,085 |
-1.16% |
Stats |
| 93 (12) |
Lovenox
Sanofi-Aventis |
178,957 |
-9.21% |
Stats |
| 94 |
Benicar
Daiichi Sankyo |
174,619 |
2.79% |
Stats |
| 95 (5) |
VESIcare
Astellas Pharma US |
174,524 |
6.58% |
Stats |
| 96 () |
Ventolin HFA
GlaxoSmithKline |
172,707 |
|
Stats |
| 97 () |
Orencia
Bristol-Myers Squibb Company |
172,202 |
|
Stats |
| 98 (1) |
Betaseron
Bayer Healthcare Pharmaceuticals |
172,143 |
2.93% |
Stats |
| 99 (2) |
Erbitux
Bristol-Myers Squibb Company |
171,513 |
2.30% |
Stats |
| 100 () |
Dexilant
Takeda Pharmaceuticals North America, Inc |
171,179 |
|
Stats |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
1)
1)
)
